Eli Lilly Inks $3.35B Collaboration with China's InnoCare
LLY sits 62% above its 52-week low of $712.05.
Summary
Eli Lilly signed a research collaboration and license agreement with Chinese drugmaker InnoCare Pharma that could be worth up to $3.35 billion. The deal expands Lilly's pipeline access in China, a key market for its obesity and diabetes franchises. This follows a string of positive developments for Lilly, including strong Q2 results and FDA approvals for Mounjaro and Foundayo. The collaboration adds another growth avenue but terms beyond the headline value are not yet disclosed.
At the time of this announcement, LLY was trading at $1,152.12 on NYSE in the Life Sciences sector, with a market capitalization of approximately $1.1T. The 52-week trading range was $712.05 to $1,292.65. This news item was assessed with positive market sentiment and an importance score of 8 out of 10. Source: Reuters.